ReNAgade Therapeutics is a biotechnology startup that operates in the field of RNA medicine. The company's main goal is to overcome the current limitations of RNA medicines, which include delivery to tissue targets and the lack of an integrated therapeutic platform. To achieve this, ReNAgade has developed a proprietary toolkit that allows them to precisely correct diseases on a large scale.

The company's business model revolves around the use of its proprietary delivery technologies to unlock previously inaccessible cells. This is achieved by reprogramming cells with superior expression using the leading RNA coding platform, in a joint venture with Orna Therapeutics.

ReNAgade's approach is unique in that it aims to enable curative therapies by permanently correcting defective genes with its proprietary technology. This is a significant step forward in the field of gene therapy, which traditionally involves the insertion of healthy genes into cells to replace defective ones.

The company's technology also allows for the insertion of exons or large genes, positioning it as a leader in the Gene Therapy 2.0 platform. This means that ReNAgade is not just treating symptoms, but is working to cure diseases at their genetic root.

ReNAgade operates in the biotechnology market, serving clients in the medical and healthcare sectors who are seeking innovative solutions to complex health problems. The company generates revenue through its joint ventures, licensing its proprietary technologies, and potentially through the development and sale of its own therapeutic products.

Keywords: RNA Medicine, Biotechnology, Gene Therapy, Proprietary Technology, Cell Reprogramming, Orna Therapeutics, Disease Correction, Healthcare, Therapeutic Platform, Exon Insertion.